

Lipid Management Options and LDL-C Reduction

Approximate reduction in LDL-C						High intensity statins (HIS) reduce LDL-C >40% (highlighted green) and are more effective at preventing cardiovascular events than low / medium intensity statins. NICE/AAC recommends atorvastatin and rosuvastatin as HIS. *Simvastatin 80mg is not recommended due to muscle toxicity risk.
Drug / daily dose	5mg	10mg	20mg	40mg	80mg	
Pravastatin (SPC) (3rd line statin if atorvastatin and rosuvastatin are inappropriate)		20%	24%	29%		
Simvastatin (SPC) (3rd line statin if atorvastatin and rosuvastatin are inappropriate)		27%	32%	37%	42%*	
Atorvastatin (SPC)		37%	43%	49%	55%	
Rosuvastatin (SPC)	38%	43%	48%	53% specialist initiation		
Atorvastatin with Ezetimibe (SPC) 10mg		52%	54%	57%	61%	
Ezetimibe 10mg with Bempedoic acid 180mg (SPC)	Approx. 38%**					**17-18% LDL-C lowering for bempedoic acid, ezetimibe 21% approximations vary in current study data.